PULMATRIX, INC. Deferred Income Tax Expense (Benefit)
PULMATRIX, INC. (PULM) reported Deferred Income Tax Expense (Benefit) of -$2.96 million for the 12-month period ending 2016-12-31, per its 10-K filed 2018-03-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2018-03-13
- PULMATRIX, INC. deferred income tax expense (benefit) for fiscal 2016 was -$2.96M.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2016-12-31 | -$2.96M 10-K · filed 2018-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |